Das Ugandaprojekt – eine deutsch-ugandische Initiative als Beispiel für transnationale medizinische Weiterbildung

U. Vehling-Kaiser(University of Applied Sciences Landshut), Ulrich Kaiser(University of Applied Sciences Landshut), Wolfgang Herr(University Hospital Regensburg), Moritz Fiedler(University of Applied Sciences Landshut), Florian Kaiser(University of Applied Sciences Landshut), Felix Kaiser(University of Applied Sciences Landshut), Raheem Esmail(TU Dortmund University), Tanja Kraus(Medical University of Graz), Veronika Kraus(University of Applied Sciences Landshut), Gamze Damnali

Forum

February 16, 2026

10.1007/s12312-026-01541-6

Cited by 0

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

|The Lancet Oncology|2015|402

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

|Annals of Oncology|2006|280

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

|Annals of Oncology|2019|194

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

|British Journal of Cancer|2020|187